Sanofi ends research in diabetes, narrows units to spur profits
Share:
PARIS (Reuters) - Sanofi on Monday said it would end its research efforts in diabetes and cardiovascular diseases as part of a reorganisation plan that will narrow the number of its global business units in the hope of bolstering growth and profits. The French drugmaker, whose pipeline has disappointed investors in recent years, poached new chief executive Paul Hudson from Swiss pharma group Novartis in September to revive momentum.That followed the recruitment of a senior head of research..